{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T21:45:06Z","timestamp":1789508706025,"version":"build-2803163510"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004385","name":"Blue Cross Blue Shield of Massachusetts","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004385","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016900","name":"Peterson Center on Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016900","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014848","name":"Arnold Ventures LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014848","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000905","name":"Commonwealth Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000905","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.schres.2024.09.023","type":"journal-article","created":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T22:25:01Z","timestamp":1727562301000},"page":"212-219","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["A network meta-analysis of KarXT and commonly used pharmacological interventions for schizophrenia"],"prefix":"10.1016","volume":"274","author":[{"given":"Abigail C.","family":"Wright","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avery","family":"McKenna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"Tice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Rind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Foluso","family":"Agboola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2024.09.023_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.jclinepi.2024.111299","article-title":"A framework for evaluating the diversity of clinical trials","volume":"169","author":"Agboola","year":"2024","journal-title":"J. Clin. Epidemiol."},{"issue":"7","key":"10.1016\/j.schres.2024.09.023_bb0010","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1017\/S1461145711001738","article-title":"Placebo-related effects in clinical trials in schizophrenia: what is driving this phenomenon and what can be done to minimize it?","volume":"15","author":"Alphs","year":"2012","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2024.09.023_bb0015","series-title":"Long-term Metabolic Outcomes Associated With KarXT (Xanomeline and Trospium): Interim Results From Pooled, Long-term Safety Studies EMERGENT-4 and EMERGENT-5","author":"Claxton","year":"2024"},{"key":"10.1016\/j.schres.2024.09.023_bb0020","series-title":"Healthcare Insights","article-title":"Most common antipsychotic medications by prescriptions dispensed","author":"Definitive Healthcare","year":"2023"},{"issue":"1","key":"10.1016\/j.schres.2024.09.023_bb0025","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"J. Clin. Epidemiol."},{"issue":"4","key":"10.1016\/j.schres.2024.09.023_bb0030","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.11m07162","article-title":"Minimum clinically important difference in the Positive and Negative Syndrome Scale with data from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE)","volume":"73","author":"Hermes","year":"2012","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2024.09.023_bb0035","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2019"},{"issue":"4","key":"10.1016\/j.schres.2024.09.023_bb0040","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S2215-0366(17)30078-0","article-title":"Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis","volume":"4","author":"Hjorth\u00f8j","year":"2017","journal-title":"Lancet Psychiatry"},{"issue":"10202","key":"10.1016\/j.schres.2024.09.023_bb0045","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.schres.2024.09.023_bb0050","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.schres.2024.09.023_bb0055","series-title":"Global Burden of Disease Study 2019 (GBD 2019)","author":"Institute for Health Metrics and Evaluation","year":"2020"},{"issue":"3","key":"10.1016\/j.schres.2024.09.023_bb0060","doi-asserted-by":"crossref","first-page":"271","DOI":"10.31887\/DCNS.2010.12.3\/ajablensky","article-title":"The diagnostic concept of schizophrenia: its history, evolution, and future prospects","volume":"12","author":"Jablensky","year":"2019","journal-title":"Dialogues Clin. Neurosci."},{"issue":"10422","key":"10.1016\/j.schres.2024.09.023_bb0065","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S0140-6736(23)02190-6","article-title":"Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial","volume":"403","author":"Kaul","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.schres.2024.09.023_bb0070","series-title":"Maintenance of Efficacy of KarXT (Xanomeline and Trospium) in Schizophrenia","author":"Kaul","year":"2024"},{"issue":"9","key":"10.1016\/j.schres.2024.09.023_bb0075","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1176\/appi.ajp.2020.177901","article-title":"The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia","volume":"177","author":"Keepers","year":"2020","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2024.09.023_bb0080","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/schbul\/sbn110","article-title":"What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it?","volume":"36","author":"Kemp","year":"2010","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2024.09.023_bb0085","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00127-018-1631-x","article-title":"A comparison of neurocognition and functioning in first episode psychosis populations: do research samples reflect the real world?","volume":"54","author":"Kline","year":"2019","journal-title":"Soc. Psychiatry Psychiatr. Epidemiol."},{"issue":"11","key":"10.1016\/j.schres.2024.09.023_bb0090","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1176\/appi.ajp.2013.13081129","article-title":"Increasing placebo response in antipsychotic drug trials: let\u2019s stop the vicious circle","volume":"170","author":"Leucht","year":"2013","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2024.09.023_bb0100","series-title":"Long-term Safety of KarXT (Xanomeline and Trospium) in Schizophrenia","author":"Marcus","year":"2024"},{"issue":"5","key":"10.1016\/j.schres.2024.09.023_bb0105","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1080\/09638237.2020.1837356","article-title":"How often do US-based schizophrenia papers published in high-impact psychiatric journals report on race and ethnicity?: A 20-year update of Lewine and Caudle (1999)","volume":"31","author":"Nagendra","year":"2022","journal-title":"J. Ment. Health"},{"key":"10.1016\/j.schres.2024.09.023_bb0110","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"12","key":"10.1016\/j.schres.2024.09.023_bb0115","doi-asserted-by":"crossref","DOI":"10.3390\/healthcare10122366","article-title":"Mortality in schizophrenia-spectrum disorders: recent advances in understanding and management","volume":"10","author":"Peritogiannis","year":"2022","journal-title":"Healthcare"},{"issue":"7","key":"10.1016\/j.schres.2024.09.023_bb0120","first-page":"904","article-title":"Economic burden in Medicaid beneficiaries with recently relapsed schizophrenia or with uncontrolled symptoms of schizophrenia not adherent to antipsychotics","volume":"27","author":"Pilon","year":"2021","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"10.1016\/j.schres.2024.09.023_bb0125","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.cpr.2018.09.004","article-title":"Diversity in randomized clinical trials of depression: a 36-year review","volume":"67","author":"Polo","year":"2019","journal-title":"Clin. Psychol. Rev."},{"issue":"4","key":"10.1016\/j.schres.2024.09.023_bb0130","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1093\/schbul\/sbaa002","article-title":"Using open questions to understand 650 people\u2019s experiences with antipsychotic drugs","volume":"46","author":"Read","year":"2020","journal-title":"Schizophr. Bull."},{"issue":"2\u20133","key":"10.1016\/j.schres.2024.09.023_bb0135","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0920-9964(01)00312-7","article-title":"Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder","volume":"57","author":"Robinson","year":"2002","journal-title":"Schizophr. Res."},{"issue":"10327","key":"10.1016\/j.schres.2024.09.023_bb0140","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0140-6736(21)01997-8","article-title":"Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis","volume":"399","author":"Schneider-Thoma","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.schres.2024.09.023_bb0145","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.schres.2024.09.023_bb0150","first-page":"18","article-title":"Which rating scales are regarded as \u2018the standard\u2019in clinical trials for schizophrenia? A critical review","volume":"44","author":"Suzuki","year":"2011","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.schres.2024.09.023_bb0155","first-page":"1","article-title":"The impact on functioning of second-generation antipsychotic medication side effects for patients with schizophrenia: a worldwide, cross-sectional, web-based survey","volume":"19","author":"Tandon","year":"2020","journal-title":"Ann. General Psychiatry"},{"key":"10.1016\/j.schres.2024.09.023_bb0160","series-title":"Evidence Report","article-title":"KarXT for schizophrenia: effectiveness and value","author":"Tice","year":"2024"}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996424004328?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996424004328?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T16:41:21Z","timestamp":1757349681000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996424004328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":31,"alternative-id":["S0920996424004328"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2024.09.023","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A network meta-analysis of KarXT and commonly used pharmacological interventions for schizophrenia","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2024.09.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}